MA43368B1 - Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales - Google Patents

Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales

Info

Publication number
MA43368B1
MA43368B1 MA43368A MA43368A MA43368B1 MA 43368 B1 MA43368 B1 MA 43368B1 MA 43368 A MA43368 A MA 43368A MA 43368 A MA43368 A MA 43368A MA 43368 B1 MA43368 B1 MA 43368B1
Authority
MA
Morocco
Prior art keywords
wnt signaling
tumor cells
biparatopic polypeptides
methods
lrp6
Prior art date
Application number
MA43368A
Other languages
English (en)
Other versions
MA43368A (fr
Inventor
Marie-Ange Buyse
Vittoria Zinzalla
Klaus-Peter Kuenkele
Karen Cromie
Stephanie Staelens
Beatrijs Strubbe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA43368A publication Critical patent/MA43368A/fr
Publication of MA43368B1 publication Critical patent/MA43368B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouveaux polypeptides de liaison réactifs en réaction croisée avec lrp5/lrp6 biparatopiques, et plus spécifiquement de nouvelles constructions de domaines variables uniques d'immunoglobuline réactives en réaction croisée avec lrp5/lrp6 biparatopiques qui peuvent inhiber les voies de signalisation wnt. L'invention concerne également des séquences spécifiques de ces polypeptides, leurs procédés de production et des procédés pour les utiliser, y compris des procédés de traitement de maladies telles que le cancer.
MA43368A 2015-12-04 2016-12-02 Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales MA43368B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15197999 2015-12-04
PCT/EP2016/079575 WO2017093478A1 (fr) 2015-12-04 2016-12-02 Polypeptides biparatopiques ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales

Publications (2)

Publication Number Publication Date
MA43368A MA43368A (fr) 2018-10-10
MA43368B1 true MA43368B1 (fr) 2020-09-30

Family

ID=54782606

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43368A MA43368B1 (fr) 2015-12-04 2016-12-02 Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
MA054648A MA54648A (fr) 2015-12-04 2016-12-02 Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA054648A MA54648A (fr) 2015-12-04 2016-12-02 Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales

Country Status (32)

Country Link
US (2) US10597449B2 (fr)
EP (2) EP3383425B1 (fr)
JP (2) JP6728355B2 (fr)
KR (1) KR102802241B1 (fr)
CN (1) CN108289943B (fr)
AR (1) AR106949A1 (fr)
AU (1) AU2016363787B2 (fr)
CL (1) CL2018001384A1 (fr)
CO (1) CO2018005680A2 (fr)
CY (1) CY1123454T1 (fr)
DK (1) DK3383425T3 (fr)
EA (1) EA201891331A1 (fr)
ES (1) ES2821099T3 (fr)
HR (1) HRP20201528T1 (fr)
HU (1) HUE051777T2 (fr)
IL (1) IL259119B (fr)
LT (1) LT3383425T (fr)
MA (2) MA43368B1 (fr)
MX (1) MX380414B (fr)
MY (1) MY200933A (fr)
PE (1) PE20181515A1 (fr)
PH (1) PH12018501155B1 (fr)
PL (1) PL3383425T3 (fr)
PT (1) PT3383425T (fr)
RS (1) RS60823B1 (fr)
SA (1) SA518391728B1 (fr)
SG (1) SG11201804510PA (fr)
SI (1) SI3383425T1 (fr)
TW (1) TWI734719B (fr)
UA (1) UA122079C2 (fr)
WO (1) WO2017093478A1 (fr)
ZA (1) ZA201802867B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013226323B2 (en) 2012-02-28 2016-07-14 Irm Llc Cancer patient selection for administration of Wnt signaling inhibitors using RNF43 mutation status
CA3132021C (fr) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Liants de pd1 et/ou lag3
KR102802241B1 (ko) 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI887192B (zh) * 2017-05-31 2025-06-21 比利時商艾伯林克斯公司 拮抗腫瘤細胞中wnt訊息傳導之多肽
WO2019032628A1 (fr) 2017-08-07 2019-02-14 The Regents Of The University Of California Plate-forme de génération d'agents thérapeutiques cellulaires sans risque
WO2019108806A1 (fr) 2017-11-29 2019-06-06 Board Of Regents Of The University Of Texas System Compositions et méthodes pour une cancérothérapie
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
EP3820906B1 (fr) * 2018-07-05 2025-10-15 Surrozen Operating, Inc. Molécules de substitution de wnt multispécifiques et leurs utilisations
WO2020080941A1 (fr) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anticorps anti-protéine 5/6 associée au récepteur de lipoprotéines de faible densité
JP2022527097A (ja) * 2019-03-29 2022-05-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ガン併用療法
TW202104258A (zh) 2019-03-29 2021-02-01 德商百靈佳殷格翰國際股份有限公司 抗癌組合療法
WO2020227071A1 (fr) 2019-05-04 2020-11-12 Inhibrx, Inc. Polypeptides se liant à cd123 et leurs utilisations
WO2020227481A1 (fr) * 2019-05-08 2020-11-12 Bluebird Bio, Inc. Immunothérapies ciblant cd123
EP4013790A4 (fr) * 2019-08-14 2023-08-23 Modmab Therapeutics Inc. Anticorps se liant à des protéines lrp6 et leurs procédés d'utilisation
CN114599679B (zh) * 2019-08-14 2024-10-18 安托拉诊疗公司 与lrp5蛋白结合的抗体及使用方法
EP4034564A4 (fr) 2019-09-23 2023-12-13 Twist Bioscience Corporation Bibliothèques d'acides nucléiques variants pour des anticorps à domaine unique
CN112794914B (zh) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 一种基于噬菌体展示技术开发的alk纳米抗体及其应用
WO2021163490A1 (fr) * 2020-02-14 2021-08-19 University Of Washington Appauvrissement ciblé de bactéries à partir de populations mélangées par l'intermédiaire d'une adhérence cellulaire programmable
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
EP4372006A4 (fr) * 2021-07-16 2025-10-08 Brightpath Biotherapeutics Co Ltd Anticorps ou dérivé d'anticorps anti-antigène tim-3, et utilisation associée
KR20250131817A (ko) * 2023-01-05 2025-09-03 하푼 테라퓨틱스, 인크. 암 치료를 위한 trop2 표적화 삼중특이적 단백질
CN116375851B (zh) * 2023-03-03 2024-03-22 中国农业科学院兰州兽医研究所 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP1274720A4 (fr) 2000-04-12 2004-08-18 Human Genome Sciences Inc Proteines fusionnees a l'albumine
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
EP1463752A4 (fr) 2001-12-21 2005-07-13 Human Genome Sciences Inc Proteines de fusion d'albumine
EP1558647B1 (fr) 2002-11-08 2015-06-10 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
WO2007140410A2 (fr) * 2006-05-30 2007-12-06 Van Andel Research Institute Récepteur 6 des lipoprotéines à faible densité (lrp6) utilisé en tant que marqueur de cellules souches mammaires et procédés associés
EP2447558B1 (fr) 2006-06-08 2013-05-29 NSK Ltd. Procédé de fabrication d'un roulement à billes à douille doté d'une bague d'étanchéité
CA2666599A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
CN100428934C (zh) 2006-09-07 2008-10-29 中国人民解放军第二军医大学 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
WO2008068280A1 (fr) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capables de se lier à des protéines sériques
CN101951954A (zh) 2007-11-02 2011-01-19 诺瓦提斯公司 调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法
CA2717015A1 (fr) 2008-03-05 2009-09-11 Ablynx Nv Nouveaux complexes dimeres de fixation a des antigenes, procedes de fabrication et utilisations associes
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
WO2010127216A2 (fr) 2009-05-01 2010-11-04 Telcodia Technologies, Inc. Détermination automatisée de quasi-identificateurs à l'aide d'une analyse de programme
US8276148B2 (en) 2009-12-04 2012-09-25 International Business Machines Corporation Continuous optimization of archive management scheduling by use of integrated content-resource analytic model
WO2011075861A1 (fr) 2009-12-23 2011-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Procédé pour faire baisser l'immunogénicité
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
US8337845B2 (en) 2010-03-03 2012-12-25 Boehringer Ingelheim International Gmbh A-beta binding polypeptides
BR112012022044A2 (pt) * 2010-03-24 2020-08-25 Genentech Inc ''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
CA2798432A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et procedes d'utilisation d'anticorps therapeutiques diriges contre la proteine 6 liee a la lipoproteine de basse densite (lrp6)
EA201291181A1 (ru) * 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
KR20140001216A (ko) * 2010-10-20 2014-01-06 제넨테크, 인크. Wnt 경로를 조절하기 위한 방법 및 조성물
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
KR20140091031A (ko) 2011-11-04 2014-07-18 노파르티스 아게 저밀도 지단백질-관련 단백질 6 (lrp6) - 반감기 연장제 구축물
JP5949270B2 (ja) 2012-07-24 2016-07-06 富士通株式会社 オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム
EP2888279A1 (fr) * 2012-08-22 2015-07-01 Glaxo Group Limited Anticorps anti-lrp6
KR102802241B1 (ko) * 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드

Also Published As

Publication number Publication date
PT3383425T (pt) 2020-10-07
EA201891331A1 (ru) 2018-12-28
LT3383425T (lt) 2020-10-12
SA518391728B1 (ar) 2022-03-28
CN108289943B (zh) 2023-06-20
MA43368A (fr) 2018-10-10
PE20181515A1 (es) 2018-09-21
US10597449B2 (en) 2020-03-24
WO2017093478A1 (fr) 2017-06-08
ES2821099T3 (es) 2021-04-23
HRP20201528T1 (hr) 2020-12-11
NZ742037A (en) 2025-07-25
US20170174762A1 (en) 2017-06-22
JP6728355B2 (ja) 2020-07-22
US11952418B2 (en) 2024-04-09
CA3006235A1 (fr) 2017-06-08
TWI734719B (zh) 2021-08-01
JP2020178701A (ja) 2020-11-05
US20200199222A1 (en) 2020-06-25
RS60823B1 (sr) 2020-10-30
AU2016363787B2 (en) 2023-02-02
IL259119B (en) 2022-04-01
EP3797790A1 (fr) 2021-03-31
DK3383425T3 (da) 2020-09-28
AR106949A1 (es) 2018-03-07
SI3383425T1 (sl) 2020-11-30
KR20180081825A (ko) 2018-07-17
EP3383425A1 (fr) 2018-10-10
MX2018006760A (es) 2018-08-01
PH12018501155A1 (en) 2019-01-28
CL2018001384A1 (es) 2018-09-14
TW201731868A (zh) 2017-09-16
ZA201802867B (en) 2026-03-25
SG11201804510PA (en) 2018-06-28
CY1123454T1 (el) 2022-03-24
PL3383425T3 (pl) 2021-01-11
CO2018005680A2 (es) 2018-06-12
AU2016363787A1 (en) 2018-05-17
HK1255725A1 (en) 2019-08-23
HUE051777T2 (hu) 2021-03-29
EP3383425B1 (fr) 2020-07-15
KR102802241B1 (ko) 2025-05-07
UA122079C2 (uk) 2020-09-10
BR112018010537A2 (pt) 2018-11-13
MX380414B (es) 2025-03-12
MA54648A (fr) 2021-11-10
CN108289943A (zh) 2018-07-17
IL259119A (en) 2018-06-28
MY200933A (en) 2024-01-24
PH12018501155B1 (en) 2024-06-28
JP2019506841A (ja) 2019-03-14

Similar Documents

Publication Publication Date Title
MA43368A (fr) Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
MX2022010224A (es) Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
EA201890278A1 (ru) Антитела к pd-l1
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MX394103B (es) Anticuerpos anti-angptl8 y usos de estos.
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
EP3579848A4 (fr) Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
WO2017136562A3 (fr) Protéines de liaison bispécifiques pour pd-l1 et kdr
CL2019003419A1 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales.
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
PH12014502184A1 (en) Anti-hla-b* 27 antibodies and uses thereof
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
FR3034420A1 (fr) Anticorps monoclonaux anti-cd303
MA41596B1 (fr) Anticorps anti-tau et leurs utilisations
EA201691384A2 (ru) Конструкции варианта sirp-альфа и их применение
EA202090513A1 (ru) Агенты, модулирующие функции бета-катенина, и связанные способы
WO2017066712A3 (fr) Modulateurs de maladie de télomères
MA39342B2 (fr) Anticorps il -21
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MA33290B1 (fr) Pipéridines substituées